J. Goldman & Co’s Repros Therapeutics Inc. RPRX Stock Holding History

J. Goldman & Co’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-350,000	Closed	-$2.6M	–	345
2015 Q3	$2.6M	Buy	+350,000	New	+$2.68M	0.22%	127
2015 Q1	–	Sell	-197,500	Closed	-$1.97M	–	359
2014 Q4	$1.97M	Buy	+197,500	New	+$1.68M	0.23%	118
2014 Q3	–	Sell	-212,500	Closed	-$3.68M	–	401
2014 Q2	$3.68M	Buy	212,500 +65,000	+44%	+$1.06M	0.27%	105
2014 Q1	$2.62M	Sell	147,500 -95,000	-39%	-$1.84M	0.19%	150
2013 Q4	$4.44M	Sell	242,500 -156,500	-39%	-$2.96M	0.56%	49
2013 Q3	$10.7M	Sell	399,000 -27,500	-6%	-$589K	1%	16
2013 Q2	$7.87M	Buy	+426,500	New	+$7.53M	0.8%	29

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

AIA

Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

J. Goldman & Co's RPRX Position: Q3 2015 in Review

J. Goldman & Co sold out of Repros Therapeutics Inc. (RPRX) in Q3 2015, closing a stake of 101,881 shares — an estimated $779K sold.

J. Goldman & Co first reported a position in RPRX in Q2 2013 and held it in 6 quarters. The position peaked at $1.75M in Q2 2013. 58 funds tracked by Wall St. Rank hold RPRX as of Q3 2015.

J. Goldman & Co reported no remaining Repros Therapeutics Inc. position as of Q3 2015 after selling out during the quarter.
J. Goldman & Co sold 101,881 Repros Therapeutics Inc. shares in Q3 2015, an estimated $779K.
J. Goldman & Co first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 6 quarters.
J. Goldman & Co's Repros Therapeutics Inc. position peaked at $1.75M in Q2 2013.
58 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q3 2015.

Based on J. Goldman & Co's 13F filing for Q3 2015, filed 16 Nov 2015.